Outlook Therapeutics
OTLK
15 hedge funds and large institutions have $18.2M invested in Outlook Therapeutics in 2016 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 4 closing their positions.
26.57% more ownership
Funds ownership: 0% → 26.57% (+27%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
17% less funds holding
Funds holding: 18 → 15 (-3)
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
43% less capital inflows, than outflows
Capital inflows: $1.53M | Capital outflows: $2.7M
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Avoro Capital Advisors
New York
|
+$814K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$651K |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$40.3K |
| 4 |
JW Asset Management
Miami Beach,
Florida
|
+$17.9K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$2.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PointState Capital
New York
|
-$850K |
| 2 |
Acuta Capital Partners
Redwood City,
California
|
-$757K |
| 3 |
Cormorant Asset Management
Boston,
Massachusetts
|
-$678K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$106K |
| 5 |
Millennium Management
New York
|
-$89.6K |
OTLK Hedge Fund Activity: Q4 2016 in Review
15 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q4 2016, worth a combined $18.2M — down 32% from $27M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of OTLK and 1 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 4 added.
The largest buyer was Avoro Capital Advisors, adding an estimated $814K. The largest seller was PointState Capital, exiting entirely with an estimated $850K sold.
- 15 institutional investors held Outlook Therapeutics (OTLK) as of Q4 2016, down from 18 in Q3 2016.
- Funds reported $18.2M of Outlook Therapeutics stock for Q4 2016, down 32% quarter-over-quarter.
- 1 fund opened new Outlook Therapeutics positions in Q4 2016 and 4 closed out, a net change of -3 holders.
- The largest Outlook Therapeutics buyer in Q4 2016 was Avoro Capital Advisors, an estimated $814K added.
- The largest Outlook Therapeutics seller in Q4 2016 was PointState Capital, an estimated $850K sold.
Based on aggregated 13F filings for Q4 2016.